4 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 3 Not applicable, 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow SARS CoV-2: new trials by email Literature Review of SARS CoV-2 trials Research Report on SARS CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin for Long COVID Syndrome Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 192 | 2026-12-01 | 2026-10-30 |
| Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19 COVID-19 Vaccines - COVID - 19, SARS CoV-2 | Phase 1 | Active not recruiting | Rokote Laboratories Finland Oy | 20 | 2026-02-10 | 2026-07-22 |
| mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes COMIRNATY® - Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2 | Phase 2 | Not yet recruiting | PharmaJet, Inc. | 40 | 2025-05-01 | 2025-04-15 |
| Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy SARS CoV-2, Developmental Disorder | Enrolling by invitation | Philipps University Marburg | 250 | 2025-04-01 | 2025-05-13 | |
| MxA-Guided Antiviral Treatment in Respiratory Viral Infections MxA tests, MxA feedback, Follow-up at Day 30 - Respiratory Viral Infections, Influenza | Not applicable | Completed | Capital Medical University | 86 | 2024-12-12 | 2026-03-04 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants GB-0669, Placebo - SARS CoV-2 | Phase 1 | Completed | Generate Biomedicines | 51 | 2023-07-18 | 2025-07-03 |
| Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB) SARS CoV-2, Liver Tumours | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 40 | 2023-05-30 | 2025-04-06 | |
| Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19) sample collection - SARS CoV-2, Kawasaki Disease | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 120 | 2021-06-10 | 2025-01-15 |
| Capturing Infectious COVID-19 Asymptomatic Cases in Singapore BD Veritor Plus System for Rapid Detection of SARS CoV-2, rt-PCR, viral culture - Covid19, SARS CoV-2 | Withdrawn | Becton, Dickinson and Company | 2021-06-01 | 2021-08-11 | ||
| Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients Human Amniotic Fluid - SARS CoV-2 | Phase 1 / Phase 2 | Completed | University of Utah | 47 | 2020-10-28 | 2023-12-21 |
| AnaConDa-therapy in COVID-19 Patients Sevoflurane - COVID-19, SARS CoV-2 | Terminated | Jeroen Bosch Ziekenhuis | 42 | 2020-10-01 | 2022-10-19 | |
| A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests Direct Antigen Tests for COVID-19 - SARS CoV-2 | Not applicable | Completed | E25Bio, Inc. | 200 | 2020-04-24 | 2020-10-19 |
COVID-19 (6) · Carcinoma, Hepatocellular (1) · Developmental Disabilities (1) · Influenza, Human (1) · Mucocutaneous Lymph Node Syndrome (1) · Retroviridae Infections (1)
Infections (8) · RNA Virus Infections (8) · Virus Diseases (8) · Respiratory Tract Diseases (7) · Respiratory Tract Infections (7) · Coronaviridae Infections (6) · Coronavirus Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6) · Adenocarcinoma (1) · Carcinoma (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1)
BNT162 Vaccine (1) · COVID-19 Nucleic Acid Testing (1) · COVID-19 Vaccines (1) · Sevoflurane (1) · Specimen Handling (1) · amniotic fluid peptide-1, human (1) · dapagliflozin (1)
Becton, Dickinson and Company (1) · Capital Medical University (1) · E25Bio, Inc. (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Generate Biomedicines (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Jeroen Bosch Ziekenhuis (1) · Ottawa Heart Institute Research Corporation (1) · PharmaJet, Inc. (1) · Philipps University Marburg (1) · Rokote Laboratories Finland Oy (1) · University of Utah (1)
United States (4) · Italy (2) · Canada (1) · China (1) · Finland (1) · Germany (1) · Netherlands (1) · Singapore (1)
Bin Cao (1) · Craig Selzman, MD (1) · D. van Nieuwenhuizen, RN (1) · Gina Remington, RN MSN (1) · Klepler N De Almeida, MD (1) · Marianna Fabi, MD (1) · Patrice Feaster, RN (1) · Yen Seow Tan, MD (1)
PMID 28954927, PMID 32315809, PMID 32395391, PMID 32404480, PMID 32422057, PMID 32485618, PMID 32497809, PMID 32504944, PMID 32542934, PMID 32577640, PMID 32585619, PMID 32636214, PMID 32646750, PMID 32800855, PMID 32823866, PMID 32845525, PMID 32960881, PMID 33574155, PMID 38066442